Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Kalaris Therapeutics Inc KLRS
$3.51
▲ +0.86%
(+$0.03)
⬆️ Above Yest. High
🎈 Low Float
🗓️ Earnings Next Week
Open
$3.43
Prev Close
$3.48
Day Range
$3.40 – $3.61
52W Range
$2.14 – $11.88
Market Cap
$76.61M
Beta
0.23
EPS (TTM)
$-2.21
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-07-30 |
| Shares Out. | 23,790,000 |
| Website | kalaristx.com/ ↗ |
| Phone | 16502492727 |
| Employees | 20 |
| Net Income | -$10.9M |
| Free Cash Flow | -$42.7M |
| Total Assets | $109.8M |
| Total Liabilities | $41.2M |
| Equity | $68.6M |
About Kalaris Therapeutics Inc
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Kalaris Therapeutics Inc is a publicly traded company under the ticker symbol KLRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)